Status:
COMPLETED
Treatment of Tinnitus With Olanzapine
Lead Sponsor:
University of Sao Paulo
Conditions:
Tinnitus
Tinnitus, Subjective
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This research aims to evaluate the effects of the drug olanzapine on the discomfort caused by tinnitus according to each patient's personality traits. Olanzapine is a drug used as an antipsychotic who...
Detailed Description
Patients will be evaluated through a standard history and otorhinolaryngological examination. Questionnaires will be used to assess tinnitus (Tinnitus Handicap Inventory) and personality (Neo Pi-R), a...
Eligibility Criteria
Inclusion
- Subjective, non-pulsatile tinnitus of at least 6 months' duration
- Stable tinnitus symptoms over the past 3 months
- Willingness to participate and provide informed consent
- Age between 18 and 70 years
Exclusion
- Active psychiatric disorders requiring pharmacological treatment
- History of psychotic illness or bipolar disorder
- Current use of antipsychotics, antidepressants, or anticonvulsants
- Severe hearing loss (threshold ≥ 80 dB in both ears)
- Substance use disorders
- Pregnancy or breastfeeding
- Known hypersensitivity to olanzapine
- Significant medical conditions (e.g., uncontrolled diabetes, hepatic impairment)
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07190482
Start Date
October 1 2023
End Date
January 20 2025
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Ethics Committee (CEP)
São Paulo, São Paulo, Brazil, 05403000